L-Prolinamide, N-(19-carboxy-1-oxononadecyl)-L-?-glutamyl-L-arginyl-L-?-aspartylglycyl-L-threonyl-L-alanyl-L-threonyl-L-lysyl-L-alanyl-L-threonyl-L-?-glutamyl-L-arginyl-L-leucyl-L-alanyl-5-carboxy-L-norvalyl-L-phenylalanyl-L-leucyl-L-glutaminyl-L-arginyl-L-seryl-L-seryl-L-phenylalanyl-N-methylglycyl-L-alanyl-N-methyl-L-isoleucyl-L-leucyl-L-seryl-L-seryl-L-threonyl-L-?-glutamyl-L-valylglycyl-L-seryl-L-asparaginyl-L-threonyl-4-hydroxy-, (3?8)-lactam, (4R)-
Healthy Volunteers
Zealand Pharmaprotein_peptidePhase 1Active
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 81/ 100
Competitive context
64 Active assets in the Healthy Volunteers cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Semaglutide Novo Nordisk A/S | Phase 4 | BB |
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE National Institute of Mental Health (NIMH) | Phase 4 | BB |
DULAGLUTIDE Novo Nordisk A/S | Phase 4 | BB |
Alpha-1-Proteinase Inhibitor Baxalta now part of Shire | Phase 4 | BB |
Risperdal University of Manchester | Phase 4 | BB |
View all 50 →
Same molecule, other indications
L-Prolinamide, N-(19-carboxy-1-oxononadecyl)-L-?-glutamyl-L-arginyl-L-?-aspartylglycyl-L-threonyl-L-alanyl-L-threonyl-L-lysyl-L-alanyl-L-threonyl-L-?-glutamyl-L-arginyl-L-leucyl-L-alanyl-5-carboxy-L-norvalyl-L-phenylalanyl-L-leucyl-L-glutaminyl-L-arginyl-L-seryl-L-seryl-L-phenylalanyl-N-methylglycyl-L-alanyl-N-methyl-L-isoleucyl-L-leucyl-L-seryl-L-seryl-L-threonyl-L-?-glutamyl-L-valylglycyl-L-seryl-L-asparaginyl-L-threonyl-4-hydroxy-, (3?8)-lactam, (4R)- is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →